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Abstract
Background: Narcolepsy with cataplexy (NC) is currently thought to be an autoimmune-mediated disorder in which
environmental risk factors make a significant contribution to its development. It was proposed that vitamin D deficiency
plays a role in autoimmune diseases. Here we investigated whether NC can be associated with 25-hydroxyvitamin D
(25(OH)D) level deficiency in patients with NC compared with gender- and age-matched normal controls.
Methodology: Serum level of 25 (OH)D was determined in 51 European patients with typical NC compared to 55 age-,
gender-, and ethnicity-matched healthy controls. Demographic and clinical data (age at onset, duration and severity of
disease at baseline, and treatment intake at time of study) and season of blood sampling were collected to control for
confounding variables.
Principal Findings: Serum 25(OH)D concentration was lower in NC compared to controls (median, 59.45 nmol/l [extreme
values 24.05–124.03] vs. 74.73 nmol/l [26.88–167.48] p=0.0039). Patients with NC had significantly greater vitamin D
deficiency (,75 nmol/l) than controls (72.5% vs 50.9%, p=0.0238). Division into quartiles of the whole sample revealed that
the risk of being affected with NC increased with lower 25(OH)D level, with a 5.34 OR [1.65–17.27] for the lowest quartile
(p=0.0051). Further adjustment for BMI did not modify the strength of the association (OR: 3.63, 95% CI=1.06–12.46,
p=0.0191). No between BMI and 25(OH)D interaction, and no correlation between 25(OH)D level and disease duration or
severity or treatment intake were found in NC.
Conclusion: We found a higher frequency of vitamin D deficiency in NC. Further studies are needed to assess the
contribution of hypovitaminosis D to the risk of developing narcolepsy, and to focus on the utility of assessing vitamin D
status to correct potential deficiency.
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Introduction
Narcolepsy with cataplexy (NC), a disease caused by loss of
hypocretin cells in the hypothalamus, is currently thought to be an
autoimmune-mediated disorder [1]. This hypothesis is based on
the close association between the HLA-DRB1*1501-DQB1*0602
haplotype [2], the strongly protective DRB1*1301-DQB1*0603
haplotype [3], the finding of polymorphisms in the T-cell receptor
alpha locus [2,3], peripubertal age at onset [4], the presence of
elevated Tribbles homolog 2 antibody levels [5], and the positive
effect of intravenous IgG to normalize CSF hypocretin-1 level
reported in a single patient with NC [6]. Thus, loss of hypocretin-
containing neurons might be attributable to an autoimmune
process. Although the precise etiology of NC remains unknown, it
is clear that both genetic and environmental factors are important
[1,7].
Vitamin D has been increasingly recognized for its pleiotropic
actions [8]. Vitamin D deficiency has been implicated in a range of
skeletal and cardiovascular diseases as well as numerous
autoimmune diseases [8]. Vitamin D receptors are present in the
brain (microglia) and in circulating immunity cells, and recent
studies confirmed this vitamin’s role in autoimmunity and
neuroprotection [8,9]. Vitamin D has been proposed as a key
environmental factor for autoimmune diseases, especially in
multiple sclerosis (MS) [9], another disease strongly associated
with the HLA-DRB1*1501-DQB1*0602 haplotype. Little is
known about the precise environmental triggers in NC.
The aim of this study was to investigate 25-hydroxyvitamin D
(25(OH)D) level in European patients with narcolepsy with typical
cataplexy compared with gender- and age-matched normal
controls.
Materials and Methods
Subjects
All subjects gave their written informed consent to participate in
the study, which was approved by the Montpellier University
Hospital’s ethics committee.
Fifty-one European patients with NC (22 males and 29 females,
16–65 y.o., median age 34.0) were included in the study.
Diagnosis was according to the revised International Classification
of Sleep Disorders (ICSD-2) [10]. All patients underwent one night
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latency tests (MSLT) the next day, consisting of five naps scheduled
at two-hour intervals starting at 9:00 a.m [12]. NC was diagnosed
based on the presence of excessive daytime sleepiness, clear-cut and
frequent cataplexy, HLA DQB1*0602 positivity, and at least two
sleep onset REM periods (SOREMPs) during the MSLT [12]. No
patients had any psychiatric disorder based on the DSM-IV criteria
or any other significant comorbid condition
We recruited 55 normal European subjects matched for age and
gender (20 males and 35 females, 21–62 y.o., median age 36.0).
All healthy controls were community-dwelling adults living in the
same area in Southern France. Inclusion criteria for controls were
the ability to understand and give informed consent, no history of
psychiatric or neurological or other organic disease, and no
daytime sleepiness (Epworth Sleepiness Scale ,11).
Demographic data (age, gender, and body mass index-BMI) and
season of blood sampling were collected on patients and controls.
Obesity was assessed on the basis of BMI calculated as weight/
height2 (kg/m2). Subjects were classified as normal, overweight or
obese according to body mass index ,25, $25, respectively [13].
Clinicaldata(ageatonset6–48years,duration of disease0–49years,
Epworth Sleepiness Scale, and frequency of cataplectic attacks),
polysomnographical data (mean sleep latency and number of
SOREMPs on theMSLT) at baseline, and the presence oftreatment
intake at time of study were gathered on the patients to control for
known and potential confounding variables. Medication at the time
of study was noted in all patients: 33 patients were untreated and 18
were taking stimulants and/or anticataplectic drugs.
Procedures
Blood and CSF sampling. Patients and controls underwent
fasting for venous blood sampling between 7:00 and 8:00 a.m.
following standardized procedures at the Montpellier Sleep
Disorders Center. Sera were separated and frozen immediately
for further analysis and were handled similarly between patients
and controls before assay. A lumbar puncture was performed in 19
patients with narcolepsy-cataplexy to measure CSF hypocretin-1
level. Hypocretin-1 peptide level was determined in duplicate from
CSF samples without prior extraction using
125I radioim-
munoassay kits (Phoenix Pharmaceuticals, Inc., Belmont, CA)
according to manufacturer’s instructions. Low CSF hypocretin-1
level, i.e. ,110 pg/ml [1], was found in all patients.
Concentration of 25-hydroxyvitamin D ergocalciferol (D2) and
cholecalciferol (D3) (25(OH)D) was measured by radioimmunoas-
say (25OH Vitamin D RIA, IDS, Immunodiagnostic Systems,
Boldon, UK). Interassay coefficient of variation was ,8.2% and
intraassay coefficient was ,6.1%. Samples were run as single
assays. The commonly accepted international norm for 25(OH)D
serum level is .75 nmol/l [9,14].
Statistical methods
The sample is described using percentages for categorical
variables and median and range for quantitative variables.
Distributions were skewed according to the Shapiro-Wilk test.
Chi square tests were used to compare categorical variables
between the two groups and the Mann-Whitney test was used for
continuous variables. Spearman’s rank order correlations were
applied to measure associations between two continuous variables.
Univariate comparisons between controls and patients with NC
were made using logistic regression analysis and quantified with
(OR) and their 95% confidence intervals (CI). Continuous
variables 25(OH)D were divided into sample quartiles and also
taken with a clinical cut-off of 75 nmol/l. Multivariate logistic
regression analyses were performed on clinical and social variables
with p-values ,0.1 in the univariate analysis. When appropriate,
interaction terms were tested using the Wald x
2 test statistic given
by the logistic regression model. Significance level was set at
p,0.05. Statistical analyses were performed using SAS software,
version 9.2 (SAS Institute, Cary, NC, USA).
Results
Variable results on demographic, clinical, and season of blood
sampling are summarized in Table 1. No group difference was
observed except for higher BMI in patients with NC (p,0.0022),
results expected as controls came from the general population.
Hence, 27.5% of patients were obese (BMI .30 kg/m
2)i n
contrast to 5.5% of controls. There was neither significant
association between gender (median 25(OH)D level (men, 64
[extreme values 28.38–123.40], and women, 71.43 [24.05–
167.48], p=0.42) 25(OH)D level in the whole population nor
age effect (median 25(OH)D level (Age,26 y.o., 64.78 [28.38–
167.48], Age 26–34, 61.70 [26.88–116.78], Age 35–48, 84.58
[24.05–124.03], and Age . 48, 64.13 [31.40–154.43], p=0.194).
However a significant correlation was found between BMI and
25(OH)D (r=20,40, p,0.0001).
Between-season sampling differences were also seen for the
median 25(OH)D level (Winter, 41.53 [extreme values 24.05–
110.95], Spring, 69.28 [34.00–167.48], Summer, 82.40 [33.95–
154.43], and Fall, 57.18 [33.90–123.83], p,0.0001).
Figure 1 illustrates the distribution of sera 25(OH)D level in
patients with NC and in controls. A significantly lower level is seen
in patients compared to normal controls (median, 59.45 nmol/l
[24.05–124.03] vs. 74.73 nmol/l [26.88–167.48] p=0.0039).
Vitamin D deficiency, defined as ,75 nmol/l, was found in
72.5% of patients compared to 50.9% of controls (p=0.0238; OR:
2.55, 95% CI=1.13–5.73). Moreover, dividing the whole
population into quartiles revealed that the risk of being affected
with narcolepsy-cataplexy increased with lower 25(OH)D level,
with a 5.34 odds ratio [1.65–17.27] for the lowest quartile
(p=0.0051) (Table 2). A low vitamin D dose-response relationship
was also found in patients with NC (p trend=0.0023). Further
adjustment for BMI (classified on two classes ,25 and $25 kg/
m
2) did not modify the strength of the association (p
trend=0.0191; odds ratio: 3.63, 95% CI=1.06–12.46) (Table
2). In addition, we failed to report any significant interaction
between BMI and 25(OH)D in patients with NC (p=0.57).
No correlation was found between 25(OH)D and age at onset,
duration of disease, Epworth Sleepiness Scale, mean sleep latency,
or number of SOREMPs on the MSLT in patients with NC.
Finally, no differences were found in 25(OH)D level with
cataplectic attack frequency or the presence of treatment intake
i.e. stimulants and/or anticataplectic drugs.
Discussion
This is the first report to investigate vitamin D status in patients
with NC. Results show significantly lower 25(OH)D level in
European patients with NC compared to age- and gender-
matched controls. Vitamin D deficiency was strongly associated
with narcolepsy by an odds ratio up to 5-fold, independently of
socio-demographic and clinical characteristics.
Serum 25(OH)D is representative of the overall vitamin D
stored in the body (D2+D3) [8]. 25(OH)D serum level differs
according to gender, BMI, skin color, season of sampling, sun
exposure duration, and food intake, and it declines with age [8].
The strength of the present analysis was in comparing vitamin D
level in patients with NC to age-, gender-, and ethnicity-matched
controls while taking into account two other potential confounding
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sera 25(OH)D level in obese subjects and in winter and fall
seasons. The effect of season of blood sampling did not differ
between patients and controls. In contrast, overweight and obesity
were more frequent in NC. However, the association between
25(OH)D level and NC persisted after adjustment for BMI, and no
between BMI and 25(OH)D interaction was found in NC.
Previous studies used cutoffs of 30–75 nmol/l for vitamin D, but
experts currently recommend a minimum clinical cutoff of
.75 nmol/l for optimal bone metabolism and other physiologic
roles of vitamin D [8,14]. However, this limit is not population-
based, and depends mainly on sunshine exposure and less on food
intake. Accordingly, vitamin D deficiency is frequently reported in
normal controls, with an overlap between normal and pathological
Table 1. Description of socio-demographic and clinical variables between normal controls and patients with narcolepsy-cataplexy.
Normal controls N=55 Narcolepsy with cataplexy N=51
n % n % p-value
Gender
Male 20 36.36 22 43.14 0.48
Female 35 63.64 29 56.86
Age (years)
,26 11 20.00 13 25.49 0.92
[26–35[ 15 27.27 13 25.49
[35–49[ 14 25.45 13 25.49
$49 15 27.27 12 23.53
BMI (kg/m
2)
,25 43 78.18 25 49.02 0.0022
$25 12 21.82 26 50.98
Season of sampling
Winter 12 21.82 12 23.53 0.13
Spring 17 30.91 15 29.41
Summer 22 40.00 13 25.49
Fall 4 7.27 11 21.57
BMI: Body Mass Index.
doi:10.1371/journal.pone.0020433.t001
Figure 1. Sera measurement of 25-hydroxyvitamin D (25(OH)D) level (in nmol/L) in patients with narcolepsy-cataplexy and age-
and gender-matched normal controls. Results are shown as a box-whisker plot, with median and 25th quartile of 25(OH)D. We noted
significantly lower level in patients compared to controls (P=0.0039).
doi:10.1371/journal.pone.0020433.g001
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were all Caucasian and resided in southern France (a notably sunny
area) we pinpointed a high frequency of vitamin D deficiency even
in normal controls (half of controls were below this threshold,
although they had significantly more vitamin D than NC patients).
How vitamin D impacts on the development of narcolepsy is still
unclear.Recent evidencehas highlighted many actions ofvitaminD
on the immune and central nervous system functions [15,16].
Vitamin D modulates the activity of regulatory T lymphocyte cells,
modifying the balance between the lymphocytes Th2 and Th1 [15].
Moreover, vitamin D was confirmed as a key environmental factor
for autoimmune diseases, especially in the thoroughly investigated
domain of MS [9]. As mentioned above, NC is considered to be an
autoimmune disease leading to loss of hypocretin-containing
neurons [1]. As suggested by low monozygotic twin concordance,
environmental risk factors appear to be highly important in
developing NC [7]. However, despite reports of streptococcal
infections in patients with recent narcolepsy onset [17], little is
known about the influence of environmental factors. As for NC, MS
is closely associated with an HLA class II gene, namely HLA
DRB1*1501, which is in tight linkage disequilibrium with
DQB1*0602 in Caucasians. Recent studies support that vitamin
D deficiency is a key factor in the causal cascade to MS [9], as the
effects of vitamin D on HLA class II gene expression with a single
vitamin D response element (VDRE) are specific to the promoter of
the HLA-DRB1*15 haplotype in MS [18]. This biological gene–
environment interaction needs to be further assessed in NC.
Numerous studies have reported that vitamin D plays a
significant immunomodulatory role in autoimmune diseases
[9,14,15]. However, the discovery of reduced serum vitamin D
level in patients with NC needs careful analysis before vitamin D is
acknowledged to play a part in its pathophysiology. For instance, it
is arguable that the hypovitaminosis D reported in NC reflects less
sun exposure due to daytime sleepiness. However, naps in NC are
typically brief and therefore unlikely to cause significantly less time
outdoors. Moreover, no vitamin D level difference was observed
between patients regarding disease severity (daytime sleepiness and
cataplexy), disease duration, or treatment intake. Finally, almost all
the controls resided in the same area (Southern France) and were
students and/or workers within the hospital being unlikely to get
more sun exposure than the patients, who were more heteroge-
neous in terms of professional occupation.
The present cross-sectional study has some limitations. First,
patients with NC were not HLA-matched to normal controls.
Because the HLA DQB1*0602 allele is present in 20% of
Caucasian controls, HLA-adjusted comparison would have
required 250 control subjects, which would have been beyond
the scope of this exploratory study. Second, sera were often taken
after a lengthy disease duration, which may have decreased the
chances of detecting hypovitaminosis D as a predictor of the
disease. However, no correlation was found between 25(OH)D
level, age at onset, and/or NC duration. Third, we were unable to
obtain sun exposure data at the time of study, during their youth,
or during gestation. Finally, this analysis did not control for dietary
vitamin intake, which is nevertheless a relatively rare practice in
France, especially in this age range.
In conclusion, we found for the first time that patients with NC
show decreased serum vitamin D level compared to matched
normal controls. Future larger sample studies should investigate
the potential pathogenic role of hypovitaminosis D as a risk factor
for NC and how it interacts in highly genetically predisposed
patients with NC to ultimately trigger the disease. The next steps
would be to study the potential vitamin D deficiency health-related
consequences, and to focus on the utility of systematically assessing
vitamin D status in patients with NC in order to correct potential
deficiency. That could be of paramount importance close to
disease onset in the aim of limiting the autoimmune process.
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